Immunitybio Stock In The News
| IBRX Stock | USD 5.10 0.06 1.19% |
Our overall analysis of Immunitybio's news coverage and content from conventional and social sources shows investors' bearish mood towards Immunitybio. The specific impact of Immunitybio news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Immunitybio's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Immunitybio headlines in addition to utilizing other, more conventional financial analysis modules. Check out Immunitybio Backtesting and Immunitybio Hype Analysis. For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.
Immunitybio |
Immunitybio Today Top News and Investor Outlook
Immunitybio Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Immunitybio and other traded companies coverage with news coverage. We help investors stay connected with Immunitybio headlines for the 22nd of November to make an informed investment decision based on correlating the impacts of news items on Immunitybio Stock performance. Please note that trading solely based on the Immunitybio hype is not for everyone as timely availability and quick action are needed to avoid losses.
Immunitybio stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Immunitybio earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Immunitybio that are available to investors today. That information is available publicly through Immunitybio media outlets and privately through word of mouth or via Immunitybio internal channels. However, regardless of the origin, that massive amount of Immunitybio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunitybio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunitybio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunitybio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunitybio alpha.
Immunitybio Largest EPS Surprises
Earnings surprises can significantly impact Immunitybio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-11-12 | 2021-09-30 | -0.2 | -0.22 | -0.02 | 10 | ||
2020-11-09 | 2020-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2020-05-11 | 2020-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2019-11-05 | 2019-09-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2024-08-06 | 2024-06-30 | -0.17 | -0.2 | -0.03 | 17 | ||
2024-05-09 | 2024-03-31 | -0.16 | -0.2 | -0.04 | 25 |
Immunitybio Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Immunitybio Stock. Current markets are strongly bullish. About 82% of major world exchanges and indexes are currently up. See today's market update for more information.
21st of November 2024
ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment at finance.yahoo.com
19th of November 2024
Wall Street Analysts Think ImmunityBio Could Surge 184.43 percent Read This Before Placing... at zacks.com
12th of November 2024
ImmunityBio Reports Third-Quarter 2024 Financial Results at businesswire.com
7th of November 2024
Oculis Holding AG Reports Q3 Loss, Lags Revenue Estimates at zacks.com
1st of November 2024
Acquisition by Blaszyk Michael D of 23430 shares of Immunitybio at 2.72 subject to Rule 16... at Blaszyk Michael D
28th of October 2024
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Phar... at benzinga.com
25th of October 2024
ImmunityBio Shares Gap Up Whats Next at thelincolnianonline.com
24th of October 2024
First Patients Dosed in Phase 1 Clinical Study of ImmunityBios CAR-NK Cell Therapy for the... at businesswire.com
23rd of October 2024
800 percent Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer F... at finance.yahoo.com
2nd of October 2024
More layoffs for ImmunityBios Dunkirk facility at bizjournals.com
30th of September 2024
Acquisition by Blaszyk Michael D of 77633 shares of Immunitybio at 5.96 subject to Rule 16... at Blaszyk Michael D
17th of September 2024
ImmunityBio Trading Down 3.2 at thelincolnianonline.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunitybio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunitybio's short interest history, or implied volatility extrapolated from Immunitybio options trading.
Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.